Matritech, Inc.

Corning Glass Works

Graham P Lidgard

Thomas E Miller

Lee Anne Beausang

Gary Toukatly

Gerald Odstrchel

Louis J Riceberg

Lee Ann Beausang

James E Ellis

Disclosed is a method for detecting and quantitating soluble nuclear matrix proteins in body fluids and extracellular media. The method is useful for monitoring the viability of cells and tissue, for evaluating the progress of a disease or its treatment, and for evaluating the cytotoxicity of unknown compounds. Also disclosed are methods for inducing the release of nuclear matrix proteins in soluble form from cells.

Nuclear matrix protein fluid assay

Disclosed are methods for determining the degree of cell death in a tissue by detecting and quantitating soluble interior nuclear matrix proteins and protein fragments in body fluids and extracellular media. The methods are is useful for monitoring the viability of cells and tissue, for evaluating the progress of a disease or its treatment, and for evaluating the cytotoxicity of unknown compounds. Also disclosed are methods for inducing the release of interior nuclear matrix proteins and protein fragments in soluble form from cells.

Disclosed are methods for determining the degree of cell death in a tissue by detecting and quantitating soluble interior nuclear matrix proteins and protein fragments in body fluids and extracellular media. The methods are useful for monitoring the viability of cells and tissue, for evaluating the progress of a disease or its treatment, and for evaluating the cytotoxicity of unknown compounds. Also disclosed are methods for inducing the release of interior nuclear matrix proteins and protein fragment in soluble form from cells.

Disclosed are genetic sequences and their encoded amino acid sequences for two interior nuclear matrix proteins useful as markers of malignant cell types. Primary and secondary structure analysis of the proteins is presented as well as means for their recombinant production, and compositions and methods for the use of these markers in clinical assays and cancer therapies.

Malignant cell type markers of the interior nuclear matrix

Disclosed is a method for evaluating the efficacy of a therapy associated with cell death in a patient undergoing such a therapy. The method involves providing at least two body fluid samples drawn from the patient, wherein a second sample is drawn from the patient after a first sample, and measuring the quantity per unit volume of a body-fluid soluble interior nuclear matrix protein in each of the samples. By comparing the quantity per unit volume of the body fluid-soluble interior nuclear matrix protein in the first sample with the quantity per unit volume of the body fluid-soluble interior nuclear matrix protein in the second sample, it is possible to determine whether there has been an increase or decrease of cell death in the patient during therapy.

Binding proteins to malignant cell type markers of the interior nuclear

Novel malignant cell type markers of the interior nuclear matrix

A radioassay procedure and reagent kit therefor for detecting auto blocking antibody, such as auto blocking antibody which interferes with the complexation of intrinsic factor with vitamin B.sub.12. A receptor, i.e., intrinsic factor, is immobilized on a support and the amount of ligand, i.e., vitamin B.sub.12, capable of binding therewith in the presence of a biological fluid sample is determined.

Growing community of inventors

Wellesley, MA, United States of America

Graham P Lidgard